Houston digital health platform Koda closes $7 million funding round

fresh funding

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

From Your Site Articles
Insight Surgery, a personalized orthopedic surgery technology company with its U.S. business operations based in Houston, has closed a series A. Photo courtesy Insight Surgery.

TMC med-tech company closes $2.5M series A, plans expansion

fresh funding

Insight Surgery, a United Kingdom-based startup that specializes in surgical technology, has raised $2.5 million in a series A round led by New York City-based life sciences investor Nodenza Venture Partners. The company launched its U.S. business in 2023 with the opening of a cleanroom manufacturing facility at Houston’s Texas Medical Center.

The startup says the investment comes on the heels of the U.S. Food and Drug Administration (FDA) granting clearance to the company’s surgical guides for orthopedic surgery. Insight says the fresh capital will support its U.S. expansion, including one new manufacturing facility at an East Coast hospital and another at a West Coast hospital.

Insight says the investment “will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.”

Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacturing of patient-specific guides for orthopedic surgery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system,” Insight CEO Henry Pinchbeck said in a news release. “This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines.”

Ross Morton, managing Partner at Nodenza, says Insight’s “disruptive” technology may enable the company to become “the leader in the personalized surgery market.”

The startup recently entered a strategic partnership with Ricoh USA, a provider of information management and digital services for businesses. It also has forged partnerships with the Hospital for Special Surgery in New York City, University of Chicago Medicine, University of Florida Health and UAB Medicine in Birmingham, Alabama.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Shreyans Chopra, founder of Mstack, is celebrating the close of his company's $40 million series A. Photo courtesy of Mstack

Innovative Houston chemicals manufacturing platform provider raises $40M series A

money moves

Houston-based Mstack, whose platform helps manufacturers source specialty chemicals, has raised $40 million in a series A funding round.

Lightspeed Venture Partners and Alpha Wave Incubation led the round, which includes a debt facility from HSBC Innovation Banking and money from several angel investors.

In a news release, Mstack says the infusion of cash will enable it to “double down on its mission to disrupt a historically flawed supply chain for specialty chemicals.”

This “doubling down” will include expansion of Mstack’s footprint in the U.S., Middle East, Latin America, and Asia.

“Geopolitical dynamics pose risks for supply chain disruptions in the global specialty chemicals market,” Bejul Somaia, a partner at Lightspeed, says in a news release.

“With demand for these chemicals growing rapidly, there is a need to increase R&D investments and unlock new pockets of supply,” he adds. “As the first institutional investor in Mstack, we believe that the company has tremendous potential to lead this transformation.”

Mstack, founded in 2022, currently serves four business sectors: oil and gas, coatings, water treatment, and home and personal care. The funding will enable it to move into industry segments such as agrochemicals and pharmaceuticals.

The Mstack platform gives buyers a one-stop shop for sourcing, testing, shipping, delivering, and tracking specialty chemicals.

“This new funding affirms investor confidence in our vision and technology to transform global markets. It enables us to expand geographically and intensify our R&D efforts,” Mstack founder Shreyans Chopra says.

Houston-based Citroniq Chemicals has secured its series A funding. Photo via Getty Images

Houston company secures $12M series A for decarbonization plant

money moves

A fresh $12 million round of funding will enable Houston-based Citroniq Chemicals to propel planning, design, and construction of its first decarbonization plant.

An unidentified multinational energy technology company led the series A round, with participation from Houston-based Lummus Technology Ventures and cooperation from the State of Nebraska. The Citroniq plant, which will produce green polypropylene, will be located in Nebraska.

“Lummus’ latest investment in Citroniq builds on this progress and strengthens our partnership, working together to lower carbon emissions in the plastics industry,” Leon de Bruyn, president and CEO of Lummus Technology, says in a news release.

Citroniq is putting together a decarbonization platform designed to annually capture 2 million metric tons of greenhouse gas emissions at each plant. The company plans to invest more than $5 billion into its green polypropylene plants. Polypropylene is a thermoplastic resin commonly used for injection molding.

The series A round “is just the first step in our journey towards building multiple biomanufacturing hubs, boosting the Nebraska bioeconomy by converting local ethanol into valuable bioplastics,” says Kelly Knopp, co-founder and CEO of Citroniq.

Citroniq’s platform for the chemical and plastics industries uses technology and U.S.-produced ethanol to enable low-cost carbon capture. Citroniq’s process permanently sequesters carbon into a useful plastic pellet.

Lummus Technology licenses process technologies for clean fuels, renewables, petrochemicals, polymers, gas processing and supply lifecycle services, catalysts, proprietary equipment, and digital transformation.

Prana Thoracic Inc., a Houston medical device company developing a tool for early interception of lung cancer, announced an additional $3 million in funding. Photo via Getty Images

Houston medtech startup secures additional $3M for lung cancer diagnostic tool

fresh funding

A Houston-based medtech startup with an innovative tool that's aiming to transform lung cancer intervention has closed its series A extension round.

Prana Thoracic announced an additional $3 million in funding, a raise that was oversubscribed by 30 percent, reports the company. The company's series A originally closed in March 2023 at $3 million. In August of 2022, the company secured $3 million in grant funding.

"We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating,” Joanna Nathan, CEO and co-founder of Prana Thoracic, says in a news release. “This additional funding will enable us to accelerate our efforts in bringing precision surgical solutions to lung cancer patients worldwide.”

The extension included participation from new investors, including cultivate(MD), GenHenn Capital, and Houston Angel Network, as well as from prior lead investor New World Angels. Existing investors — Johnson & Johnson Development Corp, Texas Medical Center Venture Fund, and the Cancer Prevention & Research Institute of Texas (CPRIT) — also support the company.

"We are excited to support Prana Thoracic in their mission to improve lung cancer treatment. Their innovative approach has the potential to significantly impact patient outcomes," says Dr. R. Sean Churchill, managing director of cultivate(MD), in the release.

The additional funding will support the company as it advances through its clinical and regulatory plans.

“The team has made remarkable progress in developing this novel and minimally invasive technique for lung tissue excision, which has the potential to transform the diagnosis and treatment of early-stage lung cancer," adds Dr. Edward M. Boyle, founder and director at the company. "Beyond lung applications, they are pioneering new methods to use this technology for other soft tissues and are actively exploring integration with ablation and robotic systems, aligning with the future direction of these fields."

In 2022, Nathan joined the Houston Innovators Podcast to discuss her passion for Prana Thoracic's innovation. Listen to the episode below.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

U.S. News names 5 Houston suburbs as the best places to retire in 2026

Retirement Report

Houston-area suburbs should be on the lookout for an influx of retirees in 2026. A new study by U.S. News and World Report has declared The Woodlands and Spring as the fourth and fifth best cities to retire in America, with three other local cities making the top 25.

The annual report, called "250 Best Places to Retire in the U.S. in 2026" initially compared 850 U.S. cities, and narrowed the list down to a final 250 cities (up from 150 previously). Each locale was analyzed across six indexes: quality of life for individuals reaching retirement age, value (housing affordability and cost of living), health care quality, tax-friendliness for retirees, senior population and migration rates, and the strength of each city's job market.

Midland, Michigan was crowned the No. 1 best place to retire in 2026. The remaining cities that round out the top five are Weirton, West Virginia (No. 2) and Homosassa Springs, Florida (No. 3).

According to U.S. News, about 15 percent of The Woodlands' population is over the age of 65. The median household income in this suburb is $139,696, far above the national average median household income of $79,466.

Though The Woodlands has a higher cost of living than many other places in the country, the report maintains that the city "offers a higher value of living compared to similarly sized cities."

"If you want to buy a house in The Woodlands, the median home value is $474,279," the city's profile on U.S. News says. "And if you're a renter, you can expect the median rent here to be $1,449." For comparison, the report says the national average home value is $370,489.

Spring ranked as the fifth best place to retire in 2026, boasting a population of more than 68,000 residents, 11 percent of whom are seniors. This suburb is located less than 10 miles south of The Woodlands, while still being far enough away from Houston (about 25 miles) for seniors to escape big city life for the comfort of a smaller community.

"Retirees are prioritizing quality of life over affordability for the first time since the beginning of the COVID-19 pandemic," said U.S. News contributing editor Tim Smart in a press release.

The median home value in Spring is lower than the national average, at $251,247, making it one of the more affordable places to buy a home in the Houston area. Renters can expect to pay a median $1,326 in monthly rent, the report added.

Elsewhere in Houston, Pearland ranked as the 17th best place to retire for 2026, followed by Conroe (No. 20) and League City (No. 25).

Other Texas cities that ranked among the top 50 best places to retire nationwide include Victoria (No. 12), San Angelo (No. 28), and Flower Mound (No. 37).

The top 10 best U.S. cities to retire in 2026 are:

  • No. 1 – Midland, Michigan
  • No. 2 – Weirton, West Virginia
  • No. 3 – Homosassa Springs, Florida
  • No. 4 – The Woodlands, Texas
  • No. 5 – Spring, Texas
  • No. 6 – Rancho Rio, New Mexico
  • No. 7 – Spring Hill, Florida
  • No. 8 – Altoona, Pennsylvania
  • No. 9 – Palm Coast, Florida
  • No. 10 – Lynchburg, Virginia
---

This article originally appeared on CultureMap.com.

Micro-nuclear reactor to launch at Texas A&M innovation campus in 2026

nuclear pilot

The Texas A&M University System and Last Energy plan to launch a micro-nuclear reactor pilot project next summer at the Texas A&M-RELLIS technology and innovation campus in Bryan.

Washington, D.C.-based Last Energy will build a 5-megawatt reactor that’s a scaled-down version of its 20-megawatt reactor. The micro-reactor initially will aim to demonstrate safety and stability, and test the ability to generate electricity for the grid.

The U.S. Department of Energy (DOE) fast-tracked the project under its New Reactor Pilot Program. The project will mark Last Energy’s first installation of a nuclear reactor in the U.S.

Private funds are paying for the project, which Robert Albritton, chairman of the Texas A&M system’s board of regents, said is “an example of what’s possible when we try to meet the needs of the state and tap into the latest technologies.”

Glenn Hegar, chancellor of the Texas A&M system, said the 5-megawatt reactor is the kind of project the system had in mind when it built the 2,400-acre Texas A&M-RELLIS campus.

The project is “bold, it’s forward-looking, and it brings together private innovation and public research to solve today’s energy challenges,” Hegar said.

As it gears up to build the reactor, Last Energy has secured a land lease at Texas A&M-RELLIS, obtained uranium fuel, and signed an agreement with DOE. Founder and CEO Bret Kugelmass said the project will usher in “the next atomic era.”

In February, John Sharp, chancellor of Texas A&M’s flagship campus, said the university had offered land at Texas A&M-RELLIS to four companies to build small modular nuclear reactors. Power generated by reactors at Texas A&M-RELLIS may someday be supplied to the Electric Reliability Council of Texas (ERCOT) grid.

Also in February, Last Energy announced plans to develop 30 micro-nuclear reactors at a 200-acre site about halfway between Lubbock and Fort Worth.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston falls from top 50 in global ranking of 'World's Best Cities'

Rankings & Reports

Houston is no longer one of the top 50 best cities in the world, according to a prestigious annual report by Canada-based real estate and tourism marketing firm Resonance Consultancy.

The newest "World's Best Cities" list dropped Houston from No. 40 last year to No. 58 for 2026.

The experts at Resonance Consultancy annually compare the world's top 100 cities with metropolitan populations of at least 1 million residents or more based on the relative qualities of livability, "lovability," and prosperity. The firm additionally collaborated with AI software company AlphaGeo to determine each city's "exposure to risk, adaptation capacity," and resilience to change.

The No. 1 best city in the world is London, with New York (No. 2), Paris (No. 3), Tokyo (No. 4), and Madrid (No. 5) rounding out the top five in 2026.

Houston at least didn't rank as poorly as it did in 2023, when the city surprisingly plummeted as the 66th best city in the world. In 2022, Houston ranked 42nd on the list.

Despite dropping 18 places, Resonance Consultancy maintains that Houston "keeps defying gravity" and is a "coveted hometown for the best and brightest on earth."

The report cited the Houston metro's ever-growing population, its relatively low median home values ($265,000 in 2024), and its expanding job market as top reasons for why the city shouldn't be overlooked.

"Chevron’s shift of its headquarters from California to Houston, backed by $100 million in renovations, crowns relocations drawn by record 2024 Port Houston throughput of more than four million containers and a projected 71,000 new jobs in 2025," the report said.

The report also draws attention to the city's diversity, spanning from the upcoming grand opening of the long-awaited Ismaili Center, to the transformation of several industrial buildings near Memorial City Mall into a mixed-use development called Greenside.

"West Houston’s Greenside will convert 35,000 square feet of warehouses into a retail, restaurant and community hub around a one-acre park by 2026, while America’s inaugural Ismaili Center remains on schedule for later this year," the report said. "The gathering place for the community and home for programs promoting understanding of Islam and the Ismaili community is another cultural jewel for the country’s most proudly diverse major city."

In Resonance Consultancy's separate list ranking "America's Best Cities," Houston fell out of the top 10 and currently ranks as the 13th best U.S. city.

Elsewhere in Texas, Austin and Dallas also saw major declines in their standings for 2026. Austin plummeted from No. 53 last year to No. 87 for 2026, and Dallas fell from No. 53 to No. 78.

"In this decade of rapid transformation, the world’s cities are confronting challenges head‑on, from climate resilience and aging infrastructure to equitable growth," the report said. "The pandemic, long forgotten but still a sage oracle, exposed foundational weaknesses – from health‑care capacity to housing affordability. Yet, true to their dynamic nature, the leading cities are not merely recovering, but setting the pace, defining new paradigms of innovation, sustainability and everyday livability."

---

This article originally appeared on CultureMap.com.

View All Listings